secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001213900-24-017770
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics secures $25M equity line with Arena; MD Anderson fund requests additional data before grant
--------------------------------------------------------------------------------

- Enters purchase agreement with Arena for up to $25M of common stock; shares priced at 90% of Market Price.
- Max advance per notice is lesser of 60% avg daily value traded (or 30% if after 8:30 ET) and $20M/$15M cap.
- Commitment fee shares equal 500,000 divided by avg VWAP over 5 days pre-ELOC reg effectiveness.
- MD Anderson's Cancer Focus Fund requested additional technical data; company expects to reapply short term, funding not assured.
- Shares issued under Section 4(a)(2)/Reg D exemption; 4.99% ownership limitation applies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024017770/0001213900-24-017770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024017770/ea0200582-8k_cerothera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-017770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer